Veradermics, Inc reported the first quarter ended March 31, 2026 results: net income Net loss was $27.2 million, for the first quarter of 2026, as compared to a net loss of $12.4 million for the first quar.
“Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.”
Equity Issuances
Veradermics, Inc issued 300,000 shares of warrant to entities affiliated with Suvretta Capital for $99.99999 per Pre-Funded Warrant.
“the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant”
Material Agreements
Veradermics, Inc entered into Purchase Agreement with certain entities affiliated with Suvretta Capital valued at approximately $30.0 million (effective 2026-04-29).
“On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million”
Earnings Releases
Veradermics, Inc reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Governance Changes
Veradermics, Inc: Amended and restated bylaws became effective upon IPO, establishing procedures for stockholder proposals and director nominations, modifying indemnification provisions, and conforming to the restated certificate (effective 2026-02-05).
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors and stockholders, became effective.”
Governance Changes
Veradermics, Inc: Fifth restated certificate of incorporation filed upon IPO, increasing authorized common stock to 200M shares, authorizing 25M preferred shares, eliminating prior preferred series references, and eliminating stockholder action by written consent (effective 2026-02-05).
“the Company filed a fifth restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective upon filing.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.